Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 2—February 2019
Research

Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans1

On This Page
Methods
Results
Discussion
Cite This Article
Figures
Figure 1
Figure 2
Figure 3
Tables
Table
Podcast
presentation_01 Listen to audio/Podcast
Downloads
Article
RIS [TXT - 2 KB]
Article Metrics
Metric Details
31
citations of this article
EID Journal Metrics on Scopus
Related Articles
Ophthalmic Sequelae of Ebola Virus Disease
Decision Algorithm for Patient Triage during Ebola
Vesicular Stomatitis Virus–Based Vaccines
More articles on Ebola
Author affiliations: University of Pittsburgh, Pittsburgh, Pennsylvania, USA (A.K. McElroy); Centers for Disease Control and Prevention, Atlanta (A.K. McElroy, P. Shrivastava-Ranjan, J.R. Harmon, R.B. Martines, L Silva-Flannery, T.D. Flietstra, S.T. Nichol, S.R. Zaki, C.F. Spiropoulou); Emory University School of Medicine, Atlanta, Georgia, USA (A.K. McElroy, C.S. Kraft, A.K. Mehta, G.M. Lyon, J.B. Varkey, B.S. Ribner)

Cite This Article

Abstract

Ebola virus disease (EVD) is associated with elevated cytokine levels, and hypercytokinemia is more pronounced in fatal cases. This type of hyperinflammatory state is reminiscent of 2 rheumatologic disorders known as macrophage activation syndrome and hemophagocytic lymphohistiocytosis, which are characterized by macrophage and T-cell activation. An evaluation of 2 cohorts of patients with EVD revealed that a marker of macrophage activation (sCD163) but not T-cell activation (sCD25) was associated with severe and fatal EVD. Furthermore, substantial immunoreactivity of host tissues to a CD163-specific antibody, predominantly in areas of extensive immunostaining for Ebola virus antigens, was observed in fatal cases. These data suggest that host macrophage activation contributes to EVD pathogenesis and that directed antiinflammatory therapies could be beneficial in the treatment of EVD.

Ebola virus (EBOV) disease (EVD) in humans is frequently severe and accompanied by fever, signs of endothelial dysfunction, coagulopathy, shock, and multisystem organ dysfunction. Data from nonhuman primate models and human autopsy cases suggest that EVD severity is not a direct effect of tissue damage resulting from destruction of infected cells because only foci of necrosis are observed (1,2). Therefore, a dysregulated immune response has been hypothesized to contribute to disease severity. The elevated levels of inflammatory cytokines and chemokines (e.g., interleukin [IL] 6, IL-8, macrophage inflammatory protein 1α and 1β, monocyte chemoattractant protein 1, and macrophage colony-stimulating factor) and immunomodulatory cytokines (e.g., IL-10 and IL-1 receptor antagonist) in fatal EVD cases certainly support this hypothesis (3–7). Hypercytokinemia accompanied by severe clinical disease seen in EVD is reminiscent of what has been described for macrophage activation syndrome (MAS) and hemophagocytic lymphohistiocytosis (HLH). The similarities between EVD and HLH have not gone unnoticed by other clinicians; a group in the Netherlands has published an opinion piece suggesting a connection between the 2 diseases (8).

HLH can occur as a primary genetic disorder or a secondary consequence of another medical condition, including infection (9). Secondary, virus-associated HLH is most commonly reported after Epstein-Barr virus (EBV) infection, and even though EBV infection is exceedingly common (seroprevalence in adults 80%–90%) (10), development of EBV-associated HLH is still a rare event, estimated at 0.4 cases/1 million population (9). Other hemorrhagic fever viruses, such as Crimean-Congo hemorrhagic fever virus (11) and dengue virus (12), have also been reported to trigger HLH.

MAS is considered a subgroup of HLH that is more commonly seen in patients with underlying systemic juvenile idiopathic arthritis. However, laboratory findings in both disorders are similar and include cytopenias of several cell types; elevated transaminases, soluble IL-2 receptor (sIL-2R), triglycerides, ferritin, soluble CD163 (sCD163), prothrombin time, partial thromboplastin time, and D-dimer; and low fibrinogen (13).

These MAS markers have been examined in patients with dengue. Elevated sCD163 and ferritin were associated with severe dengue, and sIL-2R was elevated in patients with dengue but did not distinguish between patients with severe dengue and dengue fever (14). Dengue-infected patients also had decreased monocyte-associated CD163 compared with healthy controls, consistent with the increase in sCD163 observed in their serum.

The proliferation and activation of macrophages and T cells and their secretion of proinflammatory cytokines has been proposed to contribute to the pathogenesis of both HLH and MAS. In addition, activated macrophages are sometimes noted to phagocytose erythrocytes, hence the term hemophagocytosis (13).

T-cell activation during acute EVD is significantly increased (15). EBOV interactions with T cells in vitro through T-cell immunoglobulin and mucin domain 1 (TIM-1) can promote a cytokine storm (16), and EBOV can activate macrophages in vitro though the toll-like receptor (TLR) 4 pathway (17). In an effort to determine if macrophage or T-cell activation–mediated mechanisms of pathogenesis (similar to those reported for MAS and HLH) could be contributing to EVD pathogenesis, we evaluated for the inflammatory markers present in MAS and HLH in 2 cohorts of patients with EVD.

Methods

We conducted all work with human samples under approved institutional review board protocols CDC IRB 1652, CDC IRB 6341, CDC IRB 6643, and Emory IRB00076700. Before analysis, we γ-irradiated all plasma samples with 5 × 104 Gy. We measured triglyceride levels using the Triglycerides Enzymatic Assay (XpressBio, https://xpressbio.com) according to the manufacturer’s instructions. We measured fibrinogen, ferritin, and sIL-2R as part of a multiplex immunoassay using methods previously described (3,18) and sCD163 using the Human CD163 Quantikine ELISA Kit (R&D Systems, https://www.rndsystems.com).

We obtained formalin-fixed paraffin-embedded sections of liver, heart, spleen, and testicle specimens from humans who died of EVD, specimens that were obtained from and previously evaluated by the Centers for Disease Control and Prevention (CDC; Atlanta, Georgia, USA) (2). We performed immunohistochemical stains with a mouse monoclonal antibody against CD163 (clone 10D6, dilution 1:50; Leica Biosystems, https://www.leicabiosystems.com) and polyclonal rabbit antibody against EBOV antigen (dilution 1:1,000; CDC) (19,20). We deparaffinized sections in xylene and rehydrated in a graded ethanol series. For double-stained assays, we used the EnVision G|2 Doublestain System, Rabbit/Mouse (DAB+/Permanent Red) (Dako, https://www.agilent.com/en-us/dako-products) and incubated with the CD163 monoclonal antibody and then the EBOV antibody. We performed all assays according to the manufacturers’ guidelines. We used 3,3’-diaminobenzidine (DAB) as the chromogen for the monoclonal antibody against CD163 and permanent red as the chromogen for the polyclonal antibody against EBOV. Negative control samples comprised sequential tissue sections obtained from EVD patients that were incubated with normal mouse serum stained in parallel. Also, as another control, we double-stained heart, liver, spleen, and testicle specimens from patients who died of noninfectious etiologies.

We compared biomarker levels between fatal and nonfatal cases using a previously described statistical analysis (3). In brief, we conducted an analysis of variance with use of the Bonferroni inequality and Bejamini and Hochberg false-discovery rate method to correct for multiple testing. Then, we performed model selection using stepwise regression to determine if biomarkers were significantly associated with death at the various time intervals. We performed posthoc Student t-tests for each time interval to determine statistical significance between fatal and nonfatal groups for each analyte.

Results

We compared the laboratory features of EVD with those common in MAS and HLH, including those apart from the MAS and HLH formal diagnostic criteria (21–23). Cytopenia of erythrocytes, platelets, or neutrophils are common in both MAS and HLH (Table) (13). Complete blood counts (with or without differentials) have not been performed with substantial numbers of patients with EVD, with the exception of 2 reports: 1 report on patients cared for in tertiary care settings during the West Africa outbreak (24) and 1 report including >100 patients treated during the West Africa outbreak (25). Anemia to the degree seen in HLH does not appear to be common in patients with EVD. In fact, in the large cohort from West Africa, hemoconcentration, rather than anemia, was associated with fatal outcomes (25). Few patients with EVD have thrombocytopenia <100 × 103/mL, and in the West Africa cohort, thrombocytopenia was more common in survivors. Neutropenia has been rarely seen in patients with EVD, and neutrophilia, not neutropenia, was associated with fatal outcomes in patients with EVD in West Africa. Neutrophilia could reflect the presence of a complicating secondary bacteremia that has been reported in patients with EVD (29). Therefore, the degrees of cytopenia seen in patients with EVD are more similar to those of MAS than HLH (Table).

Figure 1

Thumbnail of Laboratory findings of patients with EVD that are consistent with laboratory findings in patients with macrophage activation syndrome or hemophagocytic lymphohistiocytosis. A, B) Triglycerides; C, D) ferritin; E, F) sIL-2R; and G, H) sCD163. Levels were measured in the plasma of a series of 86 Sudan virus–infected patients (left column) or 4 Ebola virus–infected patients (right column). Solid horizontal lines indicate means. Gray shaded areas represent the level of the analyte detec

Figure 1. Laboratory findings of patients with EVD that are consistent with laboratory findings in patients with macrophage activation syndrome or hemophagocytic lymphohistiocytosis. A, B) Triglycerides; C, D) ferritin; E, F) sIL-2R; and...

A fasting hypertriglyceridemia and hypofibrinogenemia are often seen in HLH and MAS (Table) (23). Triglyceride levels had not been previously reported for EVD, so we measured them in plasma samples from EVD patients in 2 previously reported groups: 86 persons infected with Sudan virus (SUDV) during an outbreak in Gulu, Uganda, during 2000–2001 (3) (Figure 1, panel A) and 4 persons infected with EBOV treated at Emory University Hospital (Atlanta, Georgia, USA) in 2014 who survived (Figure 1, panel B) (18). Triglyceride levels were >250 mg/dL in severely ill patient EVD9, and in the SUDV-infected cohort, patients with fatal outcomes had significantly higher triglyceride levels, the caveat being that fasting triglyceride levels could not be determined. However, triglyceride levels in these patients do correlate with both severe and fatal disease. In a previous study, fibrinogen levels were measured in an EBOV cohort (18) and reported to be low in all patients, but an association with severity was not demonstrated.

Patients with MAS or HLH often have elevated ferritin (Table). As has been previously reported (3,18), ferritin levels were well above the MAS and HLH criterion in most patients with EVD (Table; Figure 1, panels C, D). Furthermore, high ferritin levels were associated with fatal outcomes in SUDV-infected patients. In fact, exceptionally high ferritin levels (>10,000 ng/mL), which were seen in many patients with EVD, have been suggested to be an independent predictor of HLH with high sensitivity and specificity (21).

sIL-2R, also known as soluble CD25, a marker of T-cell activation, has been reported to be elevated in HLH and MAS (Table). We also assessed this marker in the same 2 patient cohorts that we previously described. Many SUDV-infected patients had sIL-2R levels well above the upper limit of normal, but the level did not correlate with fatal outcome (Figure 1, panel E); all EBOV-infected patients had elevated levels of sIL-2R, regardless of disease severity, as previously reported (Figure 1, panel F) (18).

Natural killer [NK] cell activity and hemophagocytosis are often altered in HLH and MAS. Flow cytometric evaluation of NK cell populations typically reveals diminished cell numbers and function, and pathologic analysis of bone marrow biopsies or autopsy specimens might reveal evidence of hemophagocytosis. Advanced flow cytometric evaluations of peripheral blood from EBOV-infected patients were published after the West Africa outbreak (30,31), and a study reported lower numbers of total NK cells in patients with fatal cases of EVD (27). Although the activation status of the NK cells detected did not differ between those who survived and those who died, lower numbers of cells would be consistent with overall decreased NK cell activity in patients with fatal EVD. The lack of human bone marrow biopsy and autopsy specimens limited our ability to look for hemophagocytosis in EVD, but a detailed pathology study did not indicate any signs of hemophagocytosis in spleen, lymph node, or bone marrow samples from patients with EVD, although viral inclusions were noted in these tissues, specifically in cells of the mononuclear phagocytic system (2).

Measurement of sCD163, the haptoglobin-hemoglobin scavenger receptor and a marker of macrophage activation, has been examined in several studies of MAS and HLH (32–34). CD163 expression was reported on hemophagocytic macrophages in the skin of patients with HLH, and high serum levels have been noted in patients with HLH and MAS. sCD163 has also been associated with disease severity in hemorrhagic fever with renal syndrome (which occurs after hantavirus infection) and dengue hemorrhagic fever (14,35). We assessed the levels of sCD163 in the blood of patients of the SUDV and EBOV cohorts. In SUDV-infected patients, the sCD163 level was elevated (Figure 1, panel G), and high sCD163 concentration was associated with fatal outcome. The sCD163 level was high in a severely affected EBOV-infected patient (EVD9) who would not have survived without extracorporeal supportive care (Figure 1, panel H). In this patient, the peak in sCD163 occurred 19 days after symptom onset, at a point when the viremia was well controlled, having peaked at day 10 and declined thereafter (18). In fact, a strong negative correlation between viral load and sCD163 level was evident in EVD9 (Spearman correlation coefficient −0.9059). This patient remained critically ill after viral load control, suggesting that the inflammatory response was a substantial contributor to disease manifestation.

Two other laboratory findings often reported in HLH and MAS are elevated transaminases and D-dimers (Table) (13). Aspartate aminotransferase and D-dimers are elevated in patients with EVD, and elevated levels of these analytes are associated with fatal outcome (3,28).

Figure 2

Thumbnail of Immunohistochemical stains of tissue from patients with fatal cases of Ebola virus (EBOV) disease showing EBOV (red) and CD163 (brown) antigens. A) Hematoxylin and eosin stain of liver showing hepatocellular necrosis with intracytoplasmic eosinophilic inclusions (arrow). B) EBOV antigens in hepatocytes and CD163 antigens in macrophages. C) High magnification image of double immunohistochemical staining of liver tissue showing colocalization of EBOV and CD163 antigens in macrophage (

Figure 2. Immunohistochemical stains of tissue from patients with fatal cases of Ebola virus (EBOV) disease showing EBOV (red) and CD163 (brown) antigens. A) Hematoxylin and eosin stain of liver showing hepatocellular necrosis...

Given these laboratory findings suggesting an association between macrophage activation and EVD pathogenesis, we performed an analysis for CD163 protein expression with tissues from patients with fatal EVD. Liver sections from patients with fatal EVD showed hepatocyte necrosis, often with minimal inflammation (Figure 2, panel A). Mild-to-moderate small-droplet steatosis and Kupffer cell hyperplasia were also seen. Hepatocytes had characteristic intracytoplasmic eosinophilic inclusions, which were predominantly found in periportal zones and surrounding areas of necrosis.

Figure 3

Thumbnail of Double immunohistochemical staining of Ebola virus (red) and CD163 antigen (brown) in tissues of patients who died of noninfectious causes. CD163 antigens in macrophages of heart (A), liver (Kupffer cells) (B), spleen (C), and testicle (D). Original magnification ×20.

Figure 3. Double immunohistochemical staining of Ebola virus (red) and CD163 antigen (brown) in tissues of patients who died of noninfectious causes. CD163 antigens in macrophages of heart (A), liver (Kupffer cells) (B),...

We performed double-stained immunoassays to assess for colocalization of EBOV and CD163. Double staining confirmed the presence of viral antigens predominantly within hepatocytes and macrophages (Figure 2, panels B–D), as well as increased levels of CD163 in association with viral antigens. The CD163 immunostaining of the myocardium from a fatal case of EVD did not differ substantially from that of a patient who died from a noninfectious cause (Figure 2, panel E; Figure 3, panel A). Of note, CD163-positive immunostaining in the interstitial space of the testes colocalized with viral antigen (Figure 2, panel F). Tissue-resident macrophages are known to exhibit CD163 staining, so several tissue samples from patients who died of a noninfectious cause were examined to have a baseline for comparison. CD163 staining identified Kupffer cells of the liver (Figure 3, panel B), tissue-resident macrophages of the myocardium (Figure 3, panel A) and spleen (Figure 3, panel C), and macrophages in the interstitial space of the testes (Figure 3, panel D). In summary, tissues from patients with fatal EVD showed increased CD163-positive macrophages near the areas of extensive immunostaining for EBOV antigens.

Discussion

Both HLH and MAS are inflammatory syndromes that are characterized by fever, hypercytokinemia, liver dysfunction, and coagulopathy. EVD shows some striking similarities to these 2 disorders, suggesting a common underlying mechanism of pathology. T-cell activation and proliferation, evidenced by elevated sIL-2R (sCD25) levels, are hypothesized to be responsible for the bulk of the hypercytokinemia in HLH and MAS. CD25 is upregulated on activated T cells, and sCD25 levels correlate with membrane-bound CD25 levels on lymphocytes (36). The interaction between EBOV and TIM-1 on the surface of T cells has been demonstrated to lead to nonspecific T-cell activation and elevation of proinflammatory cytokines (16). However, TIM proteins are expressed on other cell types, so TIM-mediated signaling with cells other than T cells could be involved in EVD. Because all of the EVD patients we studied had elevated levels of sCD25 and T-cell activation has been reported in patients with EVD (15), hypercytokinemia could result from T-cell activation through a nonspecific component. However, a substantial amount of data suggests that T-cell function (presumably antigen-specific T-cell function) is critical for virus control and host survival (37). In addition, no correlation between sCD25 level and disease severity or outcome was evident; thus, the elevation of sCD25 might simply reflect the fact that T cells are activated after infection. Therefore, any therapeutic attempt to modulate T-cell activity to improve patient outcome must take into account the fact that different populations of T cells within the host could be simultaneously deleterious and beneficial.

In healthy persons, the ferritin level is 10–250 ng/mL and used clinically as a marker of iron storage (26). Ferritin is also known as an acute-phase reactant that is elevated nonspecifically in the context of inflammation. In HLH and MAS, ferritin levels can be markedly high. Hyperferritinemia was observed in patients with EVD, where ferritin levels were as high as 1 × 105 ng/mL, which is 3 logs of magnitude over the upper limit of normal. In HLH and MAS, the source of ferritin causing the extremely high blood levels is thought to be the activated macrophage population (38,39). In EVD, the liver could also be the source of the ferritin, as has been noted in animal models (40).

Elevations in serum triglycerides can occur in response to inflammation; this rise in concentration is thought to be mediated by cytokine-dependent increases in hepatic secretion (41). The elevated triglycerides seen in severe and fatal cases of EVD would be consistent with this finding, considering these same patients have marked increases in proinflammatory cytokines. Therefore, the finding of elevated triglycerides probably represents a response to rather than an initiator of pathology.

In contrast with the conflicting data on T-cell activation in EVD, the data for a pathogenic role of macrophages is more convincing. Elevated levels of macrophage activation marker sCD163 were seen in all patients with EVD, and this marker was associated with both disease severity and fatal outcome. Elevated levels of sCD163 in disease pathogenesis have also been reported for dengue virus and hantavirus infections (14,35), and sCD163 was an independent predictor of all-cause mortality in HIV-infected patients (42).

CD163 is shed from the surface of activated macrophages or monocytes after stimulation of surface but not intracellular TLRs (43). This shed sCD163 can then bind hemoglobin, an activity theorized to be an innate immune signaling mechanism to help combat microbial pathogens by scavenging available iron. In vivo endotoxin studies in humans have shown that surface CD163 is rapidly replaced on monocytes within 24 hours after lipopolysaccharide-mediated TLR-4 stimulation and CD163 shedding (44). Therefore, that we found elevated levels of sCD163 and abundant CD163-positive macrophages in the liver surrounding areas with extensive viral antigen is not surprising. Liver macrophages include mostly Kupffer cells, which are usual constituents of the liver, but during inflammation, monocytes are recruited from the periphery that can differentiate into macrophages in this tissue (45). Kupffer cells express various markers and are thought to have various functions. CD163 is classically considered a reparative marker of an M2 type of macrophage, but this marker is not definitive because inflammatory macrophages can also express CD163 (46). The finding of high levels of sCD163 in fatal cases of EVD and of CD163 immunostaining in association with viral antigen in the tissues of fatal cases suggests that virally mediated activation of macrophages contributes to EVD pathogenesis in vivo.

Activation of macrophages or monocytes after in vitro EBOV infection leads to massive cytokine secretion (47,48), which could also explain the hypercytokinemia that has been observed in patients with EVD. Pathogenic EBOVs and not nonpathogenic EBOV (e.g., Reston) were shown to activate macrophages by TLR-4 (17), and treatment of mice with a TLR-4 antagonist improved clinical scores, decreased inflammatory responses, and increased the survival of EBOV-infected mice (49). These in vitro and animal model data combined with the primary human data we present together provide further evidence that not only does EBOV infection activate macrophages in vivo, but this activation also plays a direct role in the pathogenesis of the virus.

A limitation of our study is that the EBOV cohort of patients treated at Emory University Hospital received several different therapeutic interventions (18). Whether these interventions affected the measured parameters is unknown; however, we noted concordance of data between patients with fatal cases of SUDV not treated with therapeutics and EVD9, the patient with severe EBV given therapeutic treatments.

Although EVD does not appear to trigger the development of MAS or HLH, the similarities of their inflammatory profile suggest that some of the therapeutic interventions that have shown success in treating HLH or MAS could be beneficial in treating EVD as well. Corticosteroids, etoposide, and cyclosporine A are mainstays for treatment of HLH, and directed biologic therapies are being assessed. A search of ClinicalTrials.gov reveals ongoing and completed studies of many novel inflammation-targeting biologics for use in either MAS or HLH: blockers of interferon-γ signaling (trial nos. NCT03311854, NCT03312751, NCT01818492, and NCT03311854), blockers of IL-6 (NCT02007239), blockers of IL-1 (NCT02780583), and antithymocyte globulin (NCT01104025). All of these therapies target inflammatory mediators or, in the case of antithymocyte globulin, T cells because T cells are thought to play a role in the pathogenesis of these inflammatory disorders. Given the acute nature of EVD, we hypothesize that targeting the specific types of inflammation seen in EVD would improve patient outcomes. The TLR-4 signaling that leads to macrophage activation is another potential target for host-directed immunotherapeutics. Clinical trials in humans are underway for biologics that block TLR-4, IL-6, IL-8, IL-1, and tumor necrosis factor α for several different disease conditions. Because all of these cytokines are elevated in EVD, we advise evaluation of these therapies in EVD. In addition, the many immunotherapeutics that modulate T-cell function, both inhibitors (e.g., IL-2 blockers) and activators (e.g., programmed cell death 1 and cytotoxic T-lymphocyte–associated protein 4 antibodies), could also be evaluated as therapeutics. Regardless of which therapeutic modality is chosen, a plethora of host immunomodulatory therapies are available and should be evaluated in nonhuman primate animal models of EVD. In fact, as the marker sCD163 indicates, inflammation can persist, even after viral load control, so improving patient outcomes will probably require both directed antiviral therapies early in the disease course and carefully timed host-directed antiinflammatory therapies.

Dr. McElroy is a pediatric infectious disease physician and a scientist who studies emerging viruses at the University of Pittsburgh, Pittsburgh, Pennsylvania, USA. She is also a guest researcher with the National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta. Her work focuses on understanding how host physiologic responses to viral infection contribute to disease.

Top

Acknowledgments

We thank Tanya Klimova for editing the manuscript.

This work was conducted while A.K.M. held a Burroughs Wellcome Career Award for Medical Scientists (1013362.01) and a National Institutes of Health K08 (AI119448). Additional support was provided by the Defense Advanced Research Projects Agency (W31P4Q-14-1-0010 to A.K.M., B.S.R., G.M.L., and C.S.K.).

Top

References

  1. Geisbert  TW, Young  HA, Jahrling  PB, Davis  KJ, Larsen  T, Kagan  E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163:2371–82. DOIPubMedGoogle Scholar
  2. Martines  RB, Ng  DL, Greer  PW, Rollin  PE, Zaki  SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2015;235:153–74. DOIPubMedGoogle Scholar
  3. McElroy  AK, Erickson  BR, Flietstra  TD, Rollin  PE, Nichol  ST, Towner  JS, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210:558–66. DOIPubMedGoogle Scholar
  4. Wauquier  N, Becquart  P, Padilla  C, Baize  S, Leroy  EM. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis. 2010;4:e837. DOIPubMedGoogle Scholar
  5. Hutchinson  KL, Rollin  PE. Cytokine and chemokine expression in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196(Suppl 2):S357–63. DOIPubMedGoogle Scholar
  6. Baize  S, Leroy  EM, Georges  AJ, Georges-Courbot  MC, Capron  M, Bedjabaga  I, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol. 2002;128:163–8. DOIPubMedGoogle Scholar
  7. Villinger  F, Rollin  PE, Brar  SS, Chikkala  NF, Winter  J, Sundstrom  JB, et al. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis. 1999;179(Suppl 1):S188–91. DOIPubMedGoogle Scholar
  8. van der Ven  AJ, Netea  MG, van der Meer  JW, de Mast  Q. Ebola virus disease has features of hemophagocytic lymphohistiocytosis syndrome. Front Med (Lausanne). 2015;2:4. DOIPubMedGoogle Scholar
  9. George  MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69–86. DOIPubMedGoogle Scholar
  10. Dowd  JB, Palermo  T, Brite  J, McDade  TW, Aiello  A. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. PLoS One. 2013;8:e64921. DOIPubMedGoogle Scholar
  11. Tasdelen Fisgin  N, Fisgin  T, Tanyel  E, Doganci  L, Tulek  N, Guler  N, et al. Crimean-Congo hemorrhagic fever: five patients with hemophagocytic syndrome. Am J Hematol. 2008;83:73–6. DOIPubMedGoogle Scholar
  12. Wan Jamaludin  WF, Periyasamy  P, Wan Mat  WR, Abdul Wahid  SF. Dengue infection associated hemophagocytic syndrome: Therapeutic interventions and outcome. J Clin Virol. 2015;69:91–5. DOIPubMedGoogle Scholar
  13. Grom  AA, Horne  A, De Benedetti  F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12:259–68. DOIPubMedGoogle Scholar
  14. Ab-Rahman  HA, Rahim  H, AbuBakar  S, Wong  PF. Macrophage activation syndrome-associated markers in severe dengue. Int J Med Sci. 2016;13:179–86. DOIPubMedGoogle Scholar
  15. McElroy  AK, Akondy  RS, Davis  CW, Ellebedy  AH, Mehta  AK, Kraft  CS, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A. 2015;112:4719–24. DOIPubMedGoogle Scholar
  16. Younan  P, Iampietro  M, Nishida  A, Ramanathan  P, Santos  RI, Dutta  M, et al. Ebola virus binding to TIM-1 on T lymphocytes induces a cytokine storm. MBio. 2017;8:e00845-17. DOIPubMedGoogle Scholar
  17. Olejnik  J, Forero  A, Deflubé  LR, Hume  AJ, Manhart  WA, Nishida  A, et al. Ebolaviruses associated with differential pathogenicity induce distinct host responses in human macrophages. J Virol. 2017;91:e00179-17. DOIPubMedGoogle Scholar
  18. McElroy  AK, Harmon  JR, Flietstra  TD, Campbell  S, Mehta  AK, Kraft  CS, et al. Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. Clin Infect Dis. 2016;63:460–7. DOIPubMedGoogle Scholar
  19. Ksiazek  TG, Rollin  PE, Jahrling  PB, Johnson  E, Dalgard  DW, Peters  CJ. Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates. J Clin Microbiol. 1992;30:947–50.PubMedGoogle Scholar
  20. Zaki  SR, Shieh  WJ, Greer  PW, Goldsmith  CS, Ferebee  T, Katshitshi  J, et al. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis. 1999;179(Suppl 1):S36–47. DOIPubMedGoogle Scholar
  21. Lehmberg  K, Ehl  S. Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br J Haematol. 2013;160:275–87. DOIPubMedGoogle Scholar
  22. Henter  JI, Horne  A, Aricó  M, Egeler  RM, Filipovich  AH, Imashuku  S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31. DOIPubMedGoogle Scholar
  23. Ravelli  A, Minoia  F, Davì  S, Horne  A, Bovis  F, Pistorio  A, et al.; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Arthritis Rheumatol. 2016;68:566–76. DOIPubMedGoogle Scholar
  24. Uyeki  TM, Mehta  AK, Davey  RT Jr, Liddell  AM, Wolf  T, Vetter  P, et al.; Working Group of the U.S.–European Clinical Network on Clinical Management of Ebola Virus Disease Patients in the U.S. and Europe. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med. 2016;374:636–46. DOIPubMedGoogle Scholar
  25. Hunt  L, Gupta-Wright  A, Simms  V, Tamba  F, Knott  V, Tamba  K, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15:1292–9. DOIPubMedGoogle Scholar
  26. Finch  CA, Bellotti  V, Stray  S, Lipschitz  DA, Cook  JD, Pippard  MJ, et al. Plasma ferritin determination as a diagnostic tool. West J Med. 1986;145:657–63.PubMedGoogle Scholar
  27. Cimini  E, Viola  D, Cabeza-Cabrerizo  M, Romanelli  A, Tumino  N, Sacchi  A, et al. Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections. PLoS Negl Trop Dis. 2017;11:e0005645. DOIPubMedGoogle Scholar
  28. Rollin  PE, Bausch  DG, Sanchez  A. Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis. 2007;196(Suppl 2):S364–71. DOIPubMedGoogle Scholar
  29. Kreuels  B, Wichmann  D, Emmerich  P, Schmidt-Chanasit  J, de Heer  G, Kluge  S, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med. 2014;371:2394–401. DOIPubMedGoogle Scholar
  30. Lüdtke  A, Ruibal  P, Becker-Ziaja  B, Rottstegge  M, Wozniak  DM, Cabeza-Cabrerizo  M, et al. Ebola virus disease is characterized by poor activation and reduced levels of circulating CD16+ monocytes. J Infect Dis. 2016;214(suppl 3):S275–80. DOIPubMedGoogle Scholar
  31. Ruibal  P, Oestereich  L, Lüdtke  A, Becker-Ziaja  B, Wozniak  DM, Kerber  R, et al. Unique human immune signature of Ebola virus disease in Guinea. Nature. 2016;533:100–4. DOIPubMedGoogle Scholar
  32. Bleesing  J, Prada  A, Siegel  DM, Villanueva  J, Olson  J, Ilowite  NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007;56:965–71. DOIPubMedGoogle Scholar
  33. Schaer  DJ, Schleiffenbaum  B, Kurrer  M, Imhof  A, Bächli  E, Fehr  J, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005;74:6–10. DOIPubMedGoogle Scholar
  34. Santos-Arroyo  A, Barrera-Llaurador  J, Sánchez  JE, Martín-García  R, Sánchez  JL. Role of skin biopsies in the diagnosis of hemophagocytic lymphohistiocytosis. Am J Dermatopathol. 2017;39:e86–9. DOIPubMedGoogle Scholar
  35. Wang  J, Guo  W, Du  H, Yu  H, Jiang  W, Zhu  T, et al. Elevated soluble CD163 plasma levels are associated with disease severity in patients with hemorrhagic fever with renal syndrome. PLoS One. 2014;9:e112127. DOIPubMedGoogle Scholar
  36. Bogner  MP, Voss  SD, Bechhofer  R, Hank  JA, Roper  M, Poplack  D, et al. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991). 1992;11:111–8. DOIPubMedGoogle Scholar
  37. McElroy  AK, Mühlberger  E, Muñoz-Fontela  C. Immune barriers of Ebola virus infection. Curr Opin Virol. 2018;28:152–60. DOIPubMedGoogle Scholar
  38. Wormsbecker  AJ, Sweet  DD, Mann  SL, Wang  SY, Pudek  MR, Chen  LY. Conditions associated with extreme hyperferritinaemia (>3000 μg/L) in adults. Intern Med J. 2015;45:828–33. DOIPubMedGoogle Scholar
  39. Cohen  LA, Gutierrez  L, Weiss  A, Leichtmann-Bardoogo  Y, Zhang  DL, Crooks  DR, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010;116:1574–84. DOIPubMedGoogle Scholar
  40. Naz  N, Moriconi  F, Ahmad  S, Amanzada  A, Khan  S, Mihm  S, et al. Ferritin L is the sole serum ferritin constituent and a positive hepatic acute-phase protein. Shock. 2013;39:520–6. DOIPubMedGoogle Scholar
  41. Feingold  KR, Hardardóttir  I, Grunfeld  C. Beneficial effects of cytokine induced hyperlipidemia. Z Ernahrungswiss. 1998;37(Suppl 1):66–74.PubMedGoogle Scholar
  42. Knudsen  TB, Ertner  G, Petersen  J, Møller  HJ, Moestrup  SK, Eugen-Olsen  J, et al. Plasma soluble CD163 level independently predicts all-cause mortality in HIV-1–infected individuals. J Infect Dis. 2016;214:1198–204. DOIPubMedGoogle Scholar
  43. Weaver  LK, Hintz-Goldstein  KA, Pioli  PA, Wardwell  K, Qureshi  N, Vogel  SN, et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol. 2006;80:26–35. DOIPubMedGoogle Scholar
  44. Hintz  KA, Rassias  AJ, Wardwell  K, Moss  ML, Morganelli  PM, Pioli  PA, et al. Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol. 2002;72:711–7.PubMedGoogle Scholar
  45. Sun  YY, Li  XF, Meng  XM, Huang  C, Zhang  L, Li  J. Macrophage phenotype in liver injury and repair. Scand J Immunol. 2017;85:166–74. DOIPubMedGoogle Scholar
  46. Barros  MH, Hauck  F, Dreyer  JH, Kempkes  B, Niedobitek  G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8:e80908. DOIPubMedGoogle Scholar
  47. Gupta  M, Mahanty  S, Ahmed  R, Rollin  PE. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1α and TNF-α and inhibit poly-IC-induced IFN-α in vitro. Virology. 2001;284:20–5. DOIPubMedGoogle Scholar
  48. Ströher  U, West  E, Bugany  H, Klenk  HD, Schnittler  HJ, Feldmann  H. Infection and activation of monocytes by Marburg and Ebola viruses. J Virol. 2001;75:11025–33. DOIPubMedGoogle Scholar
  49. Younan  P, Ramanathan  P, Graber  J, Gusovsky  F, Bukreyev  A. The toll-like receptor receptor 4 antagonist eritoran protects mice from lethal filovirus challenge. MBio. 2017;8:e00226-17. DOIPubMedGoogle Scholar

Top

Figures
Table

Top

Cite This Article

DOI: 10.3201/eid2502.181326

Original Publication Date: January 16, 2019

1Preliminary results from this study were presented at the American Association of Immunology annual meeting, May 4-8, 2018, Austin, Texas, USA.

Table of Contents – Volume 25, Number 2—February 2019

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Anita K. McElroy, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop G14, Atlanta, GA 30329-4027, USA

Send To

10000 character(s) remaining.

Top

Page created: January 16, 2019
Page updated: January 16, 2019
Page reviewed: January 16, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external